Tumor Biology

, Volume 37, Issue 1, pp 479–489 | Cite as

The role of stearoyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma

  • Hui Wang
  • Yujian Zhang
  • Yongning Lu
  • Jiajia Song
  • Min Huang
  • Jin Zhang
  • Yiran Huang
Research Article


This study aimed to investigate the correlations of stearoyl-coenzyme A desaturase 1 (SCD-1) with clear cell renal cell carcinoma (ccRCC) severity and PI3K-AKT-mTOR signaling pathway. From 2004 to 2006, tumor tissue and normal pericarcinomatous tissue from ccRCC samples were collected from ccRCC patients at Renji Hospital of Shanghai Jiaotong University. The expression of SCD-1 in the collected ccRCC samples and four cell lines (A498, 769-P, 786-O, and CAKI) was detected by Western blot. The correlation between SCD-1 expression and ccRCC severity was also analyzed by immunohistochemistry. Stable 786-O and 769-P ccRCC cells expressing SCD-1 short hairpin RNA (shRNA) were constructed, and the expression of proteins in the PI3K-AKT-mTOR signaling pathway was also detected. Finally, the inhibitory effect of PI3K-AKT-mTOR inhibitors (PI103, MK2206, rapamycin, AZD8055, and RAD001) on ccRCC cells stably expressing SCD-1 shRNA was also measured. Higher SCD-1 expression level was observed in ccRCC tissues compared with normal tissues. SCD-1 expression level was the highest in 786-O. SCD-1 expression was positively correlated with the tumor-node-metastasis (TNM) stage, grade of tumor cells, and lymphatic metastasis. There were no changes in the expression of AKT, ERK, PI3K, and PDK1. Significant differences were observed in the expression of p-AKT (at the Ser473 and Thr308 site), p-ERK, and two mTOR downstream molecules (4E-BP1 and p-P70S6K1) in cells stably expressing SCD-1 shRNA. PI103 and AZD8055 could enhance the inhibitory effect of SCD-1 interference on proliferation and migration of 786-O and 769-P cells. AZD8055 is recommended for the combined ccRCC treatment with shRNA interference.


Clear cell renal cell carcinoma Stearoyl-coenzyme A desaturase 1 PI3K-AKT-mTOR signaling pathway PI103 MK2206 Rapamycin AZD8055 RAD001 



We specially thank Dr. Meiyu Geng for her helpful discussions. This research was supported by grants from the Natural Science Foundation of China (No. 81272841), Grand New Drug Innovation Project of Shanghai Institute of Materia Medica (2012ZX09301001-007), and Shanghai Committee of Science and Technology (13ZR1425100). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of interest



  1. 1.
    Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, et al. Kidney cancer. J Natl Compr Canc Netw. 2011;9:960–77.PubMedGoogle Scholar
  2. 2.
    Störkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, et al. Classification of renal cell carcinoma. Cancer. 1997;80:987–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763–77.CrossRefPubMedGoogle Scholar
  4. 4.
    Liu X, Strable MS, Ntambi JM. Stearoyl CoA desaturase 1: role in cellular inflammation and stress. Adv Nutr (Bethesda). 2011;2:15–22.CrossRefGoogle Scholar
  5. 5.
    Morgensztern D, Mcleod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797–803.CrossRefPubMedGoogle Scholar
  6. 6.
    Osaki M, Oshimura MA, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004;9:667–76.CrossRefPubMedGoogle Scholar
  7. 7.
    Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition. J Cell Biol. 2005;171:1023–34.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Scaglia N, Igal RA. Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells. J Biol Chem. 2005;280:25339–49.CrossRefPubMedGoogle Scholar
  9. 9.
    Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9:1956–67.CrossRefPubMedGoogle Scholar
  10. 10.
    Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, et al. PI-103, a dual inhibitor of class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia. 2008;22:1698–706.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang W, Khatibi NH, Yamaguchi-Okada M, Yan J, Chen C, Hu Q, et al. Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines. Exp Neurol. 2012;233:799–806.CrossRefPubMedGoogle Scholar
  12. 12.
    Lane HA, Wood JM, Mcsheehy PM, Allegrini PR, Boulay A, Brueggen J, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009;15:1612–22.CrossRefPubMedGoogle Scholar
  13. 13.
    Sharma S, Yao H-P, Zhou Y-Q, Zhou J, Zhang R, Wang M-H. Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics. Mol Oncol. 2014;8:469–82.CrossRefPubMedGoogle Scholar
  14. 14.
    Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237–51.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hess D, Chisholm JW, Igal RA. Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells. PLoS One. 2010;5, e11394.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Park Y, Storkson JM, Ntambi JM, Cook ME, Sih CJ, Pariza MW. Inhibition of hepatic stearoyl-CoA desaturase activity by trans-10, cis-12 conjugated linoleic acid and its derivatives. Biochim Biophys Acta. 2000;1486:285–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Lyn RK, Singaravelu R, Kargman S, O’Hara S, Chan H, Oballa R, et al. Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes. Sci Rep. 2014;4:4549.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Scaglia N, Igal RA. Inhibition of stearoyl-CoA desaturase 1 expression in human lung adenocarcinoma cells impairs tumorigenesis. Int J Oncol. 2008;33:839.PubMedGoogle Scholar
  19. 19.
    Von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR, Wu K, et al. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res. 2013;19:2368–80.CrossRefGoogle Scholar
  20. 20.
    Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang B-H. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal. 2006;18:2262–71.CrossRefPubMedGoogle Scholar
  21. 21.
    She Q-B, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell. 2010;18:39–51.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab. 2011;96:E577–85.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Liu Y, Gao X, Deeb D, Gautam SC. Oleanane triterpenoid CDDO-Me inhibits Akt activity without affecting PDK1 kinase or PP2A phosphatase activity in cancer cells. Biochem Biophys Res Commun. 2012;417:570–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008;28:5422–32.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O’Reilly T, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005;120:747–59.CrossRefPubMedGoogle Scholar
  26. 26.
    Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res. 2011;71:154–63.CrossRefPubMedGoogle Scholar
  27. 27.
    Huang S, Yang ZJ, Yu C, Sinicrope FA. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. J Biol Chem. 2011;286:40002–12.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Urology, Renji Hospital, School of MedicineShanghai Jiaotong UniversityShanghaiChina
  2. 2.Division of Antitumor Pharmacology, Shanghai Institute of Materia MedicaChinese Academy of SciencesShanghaiChina

Personalised recommendations